粒细胞集落刺激因子对靶细胞的作用机制及其常用制剂的临床药理研究和应用进展(5)
[15] FUTAMI M，ZHU QS，WHICHARD ZL，et al. G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase[J]. Blood，2011，118(4)：1077-1086.
[16] KENDRICK TS，LIPSCOMBE RJ，RAUSCH O，et al. Contribution of the membrane-distal tyrosine in intracellular signaling by the granulocyte colony-stimulating factor receptor[J]. J Biol Chem，2004，279(1)：326-340.
[17] AVALOS BR. Molecular analysis of the granulocyte colony-stimulating factor receptor[J]. Blood，1996，88(3)：761-777.
, 百拇医药
[18] LI L，KLEBE D，DOYCHEVA D，et al. G-CSF ameliorates neuronal apoptosis through GSK-3β inhibition in neonatal hypoxia-ischemia in rats[J]. Exp Neurol，2015.DOI：10.1016/j.expneurol.2014.10.004.
[19] LI L，MCBRIDE DW，DOYCHEVA D，et al. G-CSF attenuates neuroinflammation and stabilizes the blood-brain barrier via the PI3K/Akt/GSK-3β signaling pathway following neonatal hypoxia-ischemia in rats[J]. Exp Neurol，2015.DOI：10.1016/j.expneurol.2014.12.020.
, http://www.100md.com
[20] KUWABARA T，KOBAYASHI S，SUGIYAMA Y. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor[J]. Drug Metab Rev，1996，28(4)：625-658.
[21] PAUL M，RAM R，KUGLER E，et al. Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients：randomized controlled trial[J]. Am J Hematol，2014，89(3)：243-248.
[22] WICZLING P，LOWE P，PIGEOLET E，et al. Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations[J]. Clin Pharmacokinet，2009，48(12)：817-826.
, 百拇医药
[23] CAI J，LI B，LIU K，et al. Low-dose G-CSF improves fat graft retention by mobilizing endogenous stem cells and inducing angiogenesis，whereas high-dose G-CSF inhibits adipogenesis with prolonged inflammation and severe fibrosis[J]. Biochem Biophys Res Commun，2017，491(3)：662-667.
[24] PETROS WP，RABINOWITZ J，STUART A，et al. Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation[J].Clin Cancer Res，1997，3(5)：705-711.
, 百拇医药
[25] BOTTERI E，KRENDYUKOV A，CURIGLIANO G. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety：a meta-analysis of randomised clinical trials in breast cancer patients[J]. Eur J Cancer，2018.DOI：10.1016/j.ejca.2017.10.034.
[26] GASC?N P，TESCH H，VERPOORT K，et al. Clinical experience with Zarzio? in Europe：what have we learned？[J]. Support Care Cancer，2013，21(10)：2925-2932., 百拇医药(李菲 王斌 舒斯云 马林)
[16] KENDRICK TS，LIPSCOMBE RJ，RAUSCH O，et al. Contribution of the membrane-distal tyrosine in intracellular signaling by the granulocyte colony-stimulating factor receptor[J]. J Biol Chem，2004，279(1)：326-340.
[17] AVALOS BR. Molecular analysis of the granulocyte colony-stimulating factor receptor[J]. Blood，1996，88(3)：761-777.
, 百拇医药
[18] LI L，KLEBE D，DOYCHEVA D，et al. G-CSF ameliorates neuronal apoptosis through GSK-3β inhibition in neonatal hypoxia-ischemia in rats[J]. Exp Neurol，2015.DOI：10.1016/j.expneurol.2014.10.004.
[19] LI L，MCBRIDE DW，DOYCHEVA D，et al. G-CSF attenuates neuroinflammation and stabilizes the blood-brain barrier via the PI3K/Akt/GSK-3β signaling pathway following neonatal hypoxia-ischemia in rats[J]. Exp Neurol，2015.DOI：10.1016/j.expneurol.2014.12.020.
, http://www.100md.com
[20] KUWABARA T，KOBAYASHI S，SUGIYAMA Y. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor[J]. Drug Metab Rev，1996，28(4)：625-658.
[21] PAUL M，RAM R，KUGLER E，et al. Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients：randomized controlled trial[J]. Am J Hematol，2014，89(3)：243-248.
[22] WICZLING P，LOWE P，PIGEOLET E，et al. Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations[J]. Clin Pharmacokinet，2009，48(12)：817-826.
, 百拇医药
[23] CAI J，LI B，LIU K，et al. Low-dose G-CSF improves fat graft retention by mobilizing endogenous stem cells and inducing angiogenesis，whereas high-dose G-CSF inhibits adipogenesis with prolonged inflammation and severe fibrosis[J]. Biochem Biophys Res Commun，2017，491(3)：662-667.
[24] PETROS WP，RABINOWITZ J，STUART A，et al. Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation[J].Clin Cancer Res，1997，3(5)：705-711.
, 百拇医药
[25] BOTTERI E，KRENDYUKOV A，CURIGLIANO G. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety：a meta-analysis of randomised clinical trials in breast cancer patients[J]. Eur J Cancer，2018.DOI：10.1016/j.ejca.2017.10.034.
[26] GASC?N P，TESCH H，VERPOORT K，et al. Clinical experience with Zarzio? in Europe：what have we learned？[J]. Support Care Cancer，2013，21(10)：2925-2932., 百拇医药(李菲 王斌 舒斯云 马林)